Amarin is a clinical-stage biopharmaceutical company with a focus on cardiovascular disease. The Company’s lead product candidate is AMR101, a prescription grade Omega-3 product comprising not less than 96% ultra-pure ethyl eicosapentaenoic acid (EPA), which is entering Phase 3 clinical trials for the treatment of hypertriglyceridemia and mixed dyslipidemia. Amarin also has next-generation lipid candidates under evaluation for preclinical development. Amarin recently established its research and development headquarters in Mystic, Connecticut with an experienced research and development team. Amarin’s programs capitalize on its lipid science expertise and the known therapeutic benefits of Omega-3 products in treating cardiovascular disease. Amarin has a number of non-core programs for partnering in the area of central nervous system (CNS) disorders, including Huntington’s disease, myasthenia gravis and Parkinson’s disease.
Type
Public
HQ
Dublin, IE
Founded
1991
Size (employees)
215 (est)
Amarin was founded in 1991 and is headquartered in Dublin, IE
Report incorrect company information

Key People/Management at Amarin

Colin Stewart

Colin Stewart

President and CEO
Joseph S. Zakrzewski

Joseph S. Zakrzewski

Executive Chairman and Chief Executive Officer
John Thero

John Thero

CFO
Declan Doogan

Declan Doogan

Chief Medical Officer

Amarin Office Locations

Amarin has offices in Dublin and Bedminster Township
Dublin, IE (HQ)
Pembroke House Pembroke Street Upper
Bedminster Township, US
1430 US-206
Show all (2)
Report incorrect company information

Amarin Financials and Metrics

Amarin Financials

Amarin's revenue was reported to be $181.10 m in FY, 2017
USD

Revenue (Q1, 2018)

43.9 m

Gross profit (Q1, 2018)

33.3 m

Gross profit margin (Q1, 2018), %

75.8%

Net income (Q1, 2018)

(24.1 m)

EBIT (Q1, 2018)

(21.9 m)

Market capitalization (14-Jun-2018)

954.1 m

Closing share price (14-Jun-2018)

3.3

Cash (31-Mar-2018)

129 m
Amarin's current market capitalization is $954.1 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

26.4 m54.2 m81.8 m130.1 m181.1 m

Revenue growth, %

106%51%59%

Cost of goods sold

11.9 m20.5 m27.9 m34.4 m45 m

Gross profit

14.4 m33.7 m53.9 m95.7 m136.2 m
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

Revenue

15.9 m17.7 m21.5 m25.5 m33.1 m32.7 m34.6 m43.9 m

Cost of goods sold

5 m5.4 m5.6 m6.4 m7.5 m6.9 m8.9 m8.5 m8.2 m10.6 m

Gross profit

10.3 m11.3 m14 m18.6 m24.3 m24.3 m26.4 m33.3 m

Gross profit Margin, %

65%64%65%73%73%74%76%76%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

191.5 m119.5 m107 m98.3 m73.6 m

Accounts Receivable

3.6 m7.8 m13.8 m20 m45.3 m

Inventories

19 m20.5 m30.3 m

Current Assets

219.4 m145.3 m143.5 m146.3 m153.3 m
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

Cash

150.5 m135.4 m161.2 m136.1 m119 m81.4 m72.5 m117.6 m96.1 m129 m

Accounts Receivable

6.4 m6.7 m8.5 m9.9 m11.2 m15 m17.6 m17.5 m29.5 m39.2 m

Inventories

16.2 m20.5 m19.7 m21.3 m20.3 m19.8 m23.9 m35.1 m

Current Assets

178 m158 m189.8 m169.3 m156.1 m124.4 m116.5 m161.2 m154.8 m207.6 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(166.2 m)(56.4 m)(115.2 m)(86.4 m)(67.9 m)

Depreciation and Amortization

246 k198 k166 k138 k62 k

Inventories

(5.4 m)13 m(5.3 m)(1.5 m)(9.8 m)

Accounts Payable

10.5 m2.4 m(652 k)(6.2 m)(6.5 m)
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

Net Income

15.3 m(26.1 m)(31.1 m)(62.6 m)(93.3 m)(29.8 m)(13.4 m)(15.8 m)(20.9 m)(24.1 m)

Depreciation and Amortization

85 k125 k8 k

Inventories

16.2 m(6.8 m)(6 m)21.3 m20.3 m19.8 m23.9 m

Accounts Payable

5.5 m6.1 m10.8 m11 k(1.4 m)15.1 m14.8 m6.9 m15.1 m(327 k)
USDY, 2018

Financial Leverage

-13 x
Show all financial metrics
Report incorrect company information